{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038592","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.809622+00:00","generated_at":"2026-05-17T17:15:29.154057+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients","bullets":["Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).","Phase 1 ELIMINATE-B trial: PBGENE-HBV showed 47-69% HBsAg reduction in all 3 Cohort 1 patients; one patient had durable ~50% reduction at 7 months.","Cohort 2 safety data showed no Grade>2 AEs; DMC recommended enrolling Cohort 3. Cash runway extended to H2 2027 via operating cost cuts of ~$25M/year.","PBGENE-DMD: FDA granted Rare Pediatric Disease and Orphan Drug designations; IND/CTA filing targeted by end of 2025 with clinical data in 2026.","Total operating expenses fell $3.9M YoY to $21.9M; cash and equivalents $84.8M as of June 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038592","json":"https://secwatch.observer/filing/0001628280-25-038592.json","markdown":"https://secwatch.observer/filing/0001628280-25-038592.md","text":"https://secwatch.observer/filing/0001628280-25-038592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828025038592/0001628280-25-038592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828025038592/dtil-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:15:29.154057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}